# Diagnostics Reference - B.56 Programme

## Qualification Diagnostics

### All Patients
| Test | Purpose | Timing |
|------|---------|--------|
| Histology | Confirm prostate adenocarcinoma | Prior to enrollment |
| CBC with differential | Baseline hematology | ≤4 weeks |
| PSA | Baseline tumor marker | ≤4 weeks |
| Testosterone | Confirm castration status | ≤4 weeks |
| Creatinine | Renal function | ≤4 weeks |
| Bilirubin | Hepatic function | ≤4 weeks |
| ALT | Hepatic function | ≤4 weeks |
| AST | Hepatic function | ≤4 weeks |
| Bone scintigraphy | Bone metastases evaluation | ≤3 months |

### Drug-Specific Additional Requirements

#### For Olaparib / Talazoparib
- **Creatinine clearance calculation** (mandatory)
- BRCA1/2 mutation testing (olaparib)
- HRR gene panel: BRCA2, ATM, CDK12, CHEK2, BRCA1, PALB2, RAD51C (talazoparib)

#### For Niraparib + Abiraterone
- **Creatinine clearance calculation** (mandatory)
- BRCA1/2 mutation testing

#### For nmCRPC (Apalutamide, Darolutamide, Enzalutamide)
- CT abdomen/pelvis (confirm M0 status)
- Chest X-ray or CT (confirm no lung metastases)
- PSA doubling time calculation (must be ≤10 months)

### Imaging Requirements

**Timing**: All imaging must be performed within 3 months before programme enrollment.

**Quality Standard**: Baseline imaging must enable subsequent objective response assessment per:
- **RECIST criteria** (soft tissue lesions)
- **PCWG criteria** (bone lesions)

| Indication | Required Imaging |
|------------|-----------------|
| mHSPC | Bone scan + CT or MRI (per clinical indication) |
| nmCRPC | Bone scan + CT abdomen/pelvis + Chest imaging |
| mCRPC | Bone scan + CT or MRI (per clinical indication) |

## Castration Status Confirmation

**Definition**: Testosterone ≤50 ng/dL (≤1.7 nmol/L)

Required for:
- nmCRPC qualification
- mCRPC qualification

## PSA Progression Criteria (for nmCRPC/mCRPC qualification)

Requires ALL of:
1. Three consecutive PSA rises
2. Measurements at least 1 week apart
3. Two rises ≥50% above nadir value
4. Absolute PSA >2 ng/mL

## Metastasis Documentation (mHSPC)

Acceptable evidence:
- Positive bone scintigraphy
- Soft tissue metastases on CT/MRI
- Visceral metastases on imaging

**Note for lymph node-only disease**: Only non-regional nodes qualify (above aortic bifurcation)

## Mutation Testing

### For Olaparib Eligibility
- Pathogenic or likely pathogenic mutation
- BRCA1 or BRCA2
- Germline OR somatic

### For Niraparib + Abiraterone Eligibility
- Pathogenic or likely pathogenic mutation
- BRCA1 or BRCA2
- Germline OR somatic

### For Talazoparib + Enzalutamide Eligibility
- Pathogenic or likely pathogenic mutation
- HRR genes: BRCA2, ATM, CDK12, CHEK2, BRCA1, PALB2, RAD51C
- Germline OR somatic
